Skip to content
Back to skills

Ppgl Partial Adrenalectomy Indication

ASecurity

This skill assesses whether partial adrenalectomy is indicated for pheochromocytoma and paraganglioma (PPGL) to preserve adrenal function in patients with familial PPGL syndrome, imaging showing bilateral adrenal tumors or high-risk genetics, or young PPGL patients desiring adrenal function preservation. Indication is considered for familial PCC, tumors ≤5 cm, or high risk of future contralateral adrenal lesions, requiring surgical expertise and informed consent regarding recurrence risk.

  • 12 stars
  • 0 votes
  • 0 copies
  • 5 views
  • Added September 9, 2026
documentationrailstestingdocumentation

Works with

  • cli

Security analysis

A100/100

Scanned September 9, 2026

npx -y skills add dromlakhani/MD2SKILL --skill ppgl-partial-adrenalectomy-indication --agent claude-code

Installs into .claude/skills of the current project.

Are you the author of Ppgl Partial Adrenalectomy Indication?

Add the live security badge to your README. It updates with every re-scan.

Security grade badge for Ppgl Partial Adrenalectomy Indication
[![Security: A — Skills Directory](https://www.skillsdirectory.com/api/skills/dromlakhani-ppgl-partial-adrenalectomy-indication/badge)](https://www.skillsdirectory.com/skills/dromlakhani-ppgl-partial-adrenalectomy-indication)

More formats (shields.io, HTML) on the badges page. Keep it an A: scan every change in CI with Pro.

Download with Pro
SKILL.md
---
name: ppgl-partial-adrenalectomy-indication
description: This skill assesses whether partial adrenalectomy is indicated for pheochromocytoma and paraganglioma (PPGL) to preserve adrenal function in patients with familial PPGL syndrome, imaging showing bilateral adrenal tumors or high-risk genetics, or young PPGL patients desiring adrenal function preservation. Indication is considered for familial PCC, tumors ≤5 cm, or high risk of future contralateral adrenal lesions, requiring surgical expertise and informed consent regarding recurrence risk.
---

# Partial Adrenalectomy Indication Assessment for PPGL

## STEP 1 — Gather Information
Collect: family history of PPGL syndrome (VHL, MEN2, RET, SDHx), genetic testing results, imaging (CT/MRI) showing bilateral adrenal tumors or unilateral lesion with high-risk contralateral genetics, tumor size (≤5 cm vs >5 cm), patient age, patient preference for adrenal preservation, surgeon expertise in partial adrenalectomy, and documentation of informed consent discussion regarding recurrence and steroid dependence risk.

## STEP 2 — Rule In / Rule Out
Is there a familial PPGL syndrome, bilateral adrenal tumors/high-risk genetics, tumor ≤5 cm, or a young patient desiring adrenal preservation? If yes, proceed to Step 3; if no, partial adrenalectomy is not indicated.

## STEP 3 — Classify or Stratify
Classify as suitable for partial adrenalectomy if tumor ≤5 cm, surgeon has expertise in partial adrenalectomy, and informed consent obtained; otherwise classify as unsuitable (tumor >5 cm, insufficient expertise, or lack of consent).

## STEP 4 — Decide
If suitable, proceed with partial adrenalectomy; if unsuitable, perform total adrenalectomy or consider alternative surgical approach.

## Clinical Guardrails / Mimics / Pitfalls
Do not perform partial adrenalectomy in tumors >5 cm, in surgeons without specific expertise, without documented informed consent, or in sporadic PPGL lacking high-risk genetics/bilateral disease; avoid ignoring recurrence risk (ipsilateral tumor recurrence ~13%) and steroid dependence (23.5% postoperative).

## Concrete Clinical Example
A 28‑year‑old patient with a known VHL pathogenic variant presents with a 4 cm left adrenal tumor and normal right adrenal gland; genetic counseling confirms high risk of contralateral lesion, the patient desires adrenal preservation, and an experienced endocrine surgeon is available. After informed consent discussing recurrence and steroid dependence risks, a left partial adrenalectomy is performed.

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

Attribution

Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.

Comments

Loading comments…

Newsletter

Get the weekly list of safe new skills, and the ones we pulled.